Patent application number | Description | Published |
20090047167 | Iron-Nickel Alloy - Disclosed is a creep-resistant low-expansion iron-nickel alloy that is provided with increased mechanical resistance and contains 40 to 43 wt. % of Ni, a maximum of 0.1 wt. % of C, 2.0 to 3.5 wt. % of Ti, 0.1 to 1.5 wt. % of Al, 0.1 to 1.0 wt. % of Nb, 0.005 to 0.8 wt. % of Mn, 0.005 to 0.6 wt. % of Si, a maximum of 0.5 wt. % of Co, the remainder being composed of Fe and production-related impurities. Said alloy has a mean coefficient of thermal expansion <5×10<−6>/K in the temperature range of 20 to 200 DEG C. | 02-19-2009 |
20100059145 | METAL FOIL - The invention relates to a metal foil having (in weight %) Ni 74-90%, W 10-26%, and Al and/or Mg and/or B contents of Al >0-max. 0.02%, Mg >0-max. 0.025%, B>0-max. 0.005%. | 03-11-2010 |
20100175847 | Iron-Nickel-Cobalt Alloy - Use of an iron-nickel-cobalt alloy in CFC mould construction comprising (in % by mass) Ni from 30 to 35%, Co from 3 to 6%, Al from 0.001 to 0.1%, Mn from 0.005 to 0.5%, Si from 0.005 to 0.5%, C max. 0.1%, balance Fe and constituents resulting from production, with the alloy having a mean coefficient of thermal expansion in the temperature range from 20 to 200 DEG C of <2.0 OE10<−6>/K. | 07-15-2010 |
20110056589 | IRON-NICKLE ALLOY - Disclosed is an iron-nickel alloy having the following composition, in % by mass: C 0.05 to 0.5%, Cr 0.2 to 2.0%, Ni 33 to 42%, Mn<0.1%, Si<0.1%, Mo 1.5 to 4.0%, Nb 0.01 to 0.5%, Al 0.1 to 0.8%, Mg 0.001 to 0.01%, V max. 0.1%, W 0.1 to 1.5%, Co max. 2.0%, the remainder Fe, and production-related impurities. | 03-10-2011 |
Patent application number | Description | Published |
20090069196 | Prediction of Breast Cancer Response to Chemotherapy - Method for the prediction of the response to epirubicin/cyclophosphamide-based chemotherapy of a breast cancer in a patient, from a tumour sample of said patient, comprising steps of determining the expression level of a group of marker genes consisting of (i) a first marker gene selected from the group consisting of MLPH, SPDEF, and AKR7A3; and (ii) a pair of second marker genes selected from the group of pairs consisting of (H2BFS and UBE2S), (BGN and ZBTB16), (ZBTB16 and EMP1), (LGALS8 and UBE2S) and (OLFML2B and ZBTB16); and (iii) a third marker gene selected from the group consisting of CYBA, ACP5, a gene specifically binding to Affymetrix probe set ID 210915 x at, LCK, GSTM3; classifying said sample as belonging to one of several breast cancer response classes from the expression levels determined; predicting the response of said breast cancer in said patient to chemotherapy from previously known characteristic properties of tumours of said one of several breast cancer response classes. | 03-12-2009 |
20090130678 | Methods and Kits for Breast Cancer Prognosis - The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient. | 05-21-2009 |
20090222387 | Diagnosis, Prognosis and Prediction of Recurrence of Breat Cancer - The present invention relates to methods and compositions for the diagnosis, prognosis, and prediction of breast cancer. More specifically, the invention relates to classification of breast cancer tissue samples based on measuring the expression of a set of marker genes. The set is useful for the identification of clinically important breast cancer subtypes. Methods are disclosed for prediction, diagnosis and prognosis of breast cancer. | 09-03-2009 |
20090239223 | Prediction of Breast Cancer Response to Taxane-Based Chemotherapy - The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy. | 09-24-2009 |
20090311700 | Methods for Breast Cancer Prognosis - The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer. | 12-17-2009 |
20110143946 | Method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent - The present invention relates to a method for predicting a response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the pattern of expression level of at least one gene of the group comprising AKR1C1, MLPH, ESR1, PGR, COMP, DCN, IGKC, CCL5, FBN1 and/or UBE2C, or of genes coregulated therewith, in said sample; c) comparing the pattern of expression levels determined in (b) with one or several reference pattern (s) of expression levels; d) identifying at least one marker gene; e) determining a molecular subtype for said sample on the basis of (d); and f) predicting from said molecular subtype response of a tumor for a chemotherapeutic agent, wherein the molecular subtype is selected from the group comprising the subtypes basal, stromal-high, stromal-low, luminal A, immune system-high, immune system-low, proliferation-high and/or proliferation-low. | 06-16-2011 |
20110166838 | ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER - The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A. | 07-07-2011 |
20110172928 | MOLECULAR MARKERS FOR CANCER PROGNOSIS - The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF. | 07-14-2011 |
20120034629 | PREDICTION OF NON-FATAL AND FATAL ATHEROTHROMBOTIC EVENTS - The present invention relates to methods and systems for the prediction of atherothrombotic events in human subjects. Preferably the human subjects are afflicted with a cardiovascular disease, such as end-stage renal disease. Methods and systems of the invention are particularly suited to predict atherothrombotic events in patients on hemodialysis. | 02-09-2012 |